

IN THE CLAIMS

Claims 100 has been amended. Claims 102-104, 109-111, 114, 115, 117, and 119 have been cancelled. Claims 100, 105-107, 112, 116, and 120-128 are pending in the present application. The following is the status of the claims of the above-captioned application, as amended.

1-99 (Cancelled)

100. (Currently Amended) An isolated nucleic acid sequence encoding a ~~naturally occurring~~ polypeptide having phospholipase B activity comprising amino acids 20 to 464 of SEQ ID NO: 2; ~~selected from the group consisting of:~~

~~— (a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 90% identity with amino acids 20 to 464 of SEQ ID NO: 2;~~

~~— (b) a nucleic acid sequence having at least 90% homology with nucleotides 568 to 2045 of SEQ ID NO: 1; and~~

~~— (c) a nucleic acid sequence which hybridizes under medium-high stringency conditions with (i) nucleotides 568 to 2045 of SEQ ID NO: 1, (ii) the cDNA sequence contained in nucleotides 568 to 2045 of SEQ ID NO: 1, or (iii) a complementary strand of (i) or (ii).~~

101. (Cancelled)

102. (Cancelled).

103. (Cancelled).

104. (Cancelled).

105. (Previously Presented) The nucleic acid sequence of claim 100, which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

106. (Previously Presented) The nucleic acid sequence of claim 100, which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment thereof

which has phospholipase B activity.

107. (Previously Presented) The nucleic acid sequence of claim 106, which encodes a polypeptide consisting of amino acids 20 to 464 of SEQ ID NO: 2.

108. (Cancelled)

109. (Cancelled).

110. (Cancelled).

111. (Cancelled).

112. (Previously Presented) The nucleic acid sequence of claim 100, comprising the nucleic acid sequence of nucleotides 568 to 2045 of SEQ ID NO: 1.

113. (Cancelled)

114. (Cancelled).

115. (Cancelled).

116. (Previously Presented) The nucleic acid sequence of claim 100, contained in *E. coli* pPH6 as deposited with NRRL under accession number B-30142.

117. (Cancelled).

118. (Cancelled)

119. (Cancelled).

120. (Previously Presented) A nucleic acid construct comprising the nucleic acid sequence of claim 100 operably linked to one or more control sequences which direct the production of the polypeptide in a suitable expression host.

121. (Previously Presented) A recombinant expression vector comprising the nucleic acid construct of claim 120.

122. (Previously Presented) A recombinant host cell comprising the nucleic acid construct of claim 120.

123. (Previously Presented) A method for producing a polypeptide having phospholipase B activity comprising (a) cultivating a strain comprising the nucleic acid sequence of claim 100 under conditions suitable for producing the polypeptide; and (b) recovering the polypeptide.

124. (Previously Presented) A method for producing a polypeptide having phospholipase B activity comprising (a) cultivating the recombinant host cell of claim 122 under conditions suitable for production of the polypeptide; and (b) recovering the polypeptide.

125. (Previously Presented) A nucleic acid construct comprising a gene encoding a protein operably linked to a nucleic acid sequence encoding a signal peptide consisting of nucleotides 510 to 567 of SEQ ID NO. 1, wherein the gene is foreign to the nucleic acid sequence.

126. (Previously Presented) A recombinant expression vector comprising the nucleic acid construct of claim 125.

127. (Previously Presented) A recombinant host cell comprising the nucleic acid construct of claim 125.

128. (Previously Presented) A method for producing a protein comprising (a) cultivating the recombinant host cell of claim 127 under conditions suitable for production of the protein; and (b) recovering the protein.